Evotec SE FY2025 Results, $100M Gilead Deal, Weak 2026 Outlook

Evotec SE posted FY2025 revenue €788 million, within guidance €760‑€800 million and above consensus €774 million.
Adjusted EBITDA reached €41 million, beating consensus €27 million and sitting inside guidance €30‑€50 million.
2026 outlook is weak, with revenue €700‑€780 million and EBITDA €0‑€40 million, described as a transition year.
Evotec will receive $100 million upfront from Gilead’s acquisition of Tubulis and plans €75 million run‑rate savings by 2027.